United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - abatacept - powder for solution for infusion - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - abatacept - solution for injection - 125mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - abatacept - solution for injection - 125mg/1ml

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - powder for concentrate for solution for infusion - abatacept 250 mg - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists. polyarticular juvenile idiopathic arthritis: orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).orencia is indicated for the prophylaxis of acute graft versus host disease (agvhd), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 6 years of age or older undergoing hematopoietic stem cell transplantation (hsct) from a matched or 1 allele-mismatched unrelated-donor.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - solution for injection - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).

Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - abatacept - injection, powder, lyophilized, for solution - 262.5mg

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - abatacept - arthritis, psoriatic; arthritis, juvenile rheumatoid; arthritis, rheumatoid - immunosuppressants - rheumatoid arthritisorencia, in combination with methotrexate, is indicated for:the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) including methotrexate (mtx) or a tumour necrosis factor (tnf)-alpha inhibitor.the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.psoriatic arthritisorencia, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis (psa) in adult patients when the response to previous dmard therapy including mtx has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required. polyarticular juvenile idiopathic arthritisorencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pjia) in paediatric patients 2 years of age and older who have had an inadequate response to previous dmard therapy.orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.

Canada - English - Health Canada

bristol-myers squibb canada - abatacept - powder for solution - 250mg - abatacept 250mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

bristol-myers squibb canada - abatacept - solution - 125mg - abatacept 125mg - immunosuppressive agents

Canada - English - Health Canada

bristol-myers squibb canada - abatacept - solution - 125mg - abatacept 125mg - immunosuppressive agents